ValueAligned Portfolio Results
+34.4% in 2013; +3.4% Since Year’s End
What’s up? The ValueAligned® Model Portfolio.
The VAP was +34.4% last year, handily beating our +15% per year goal. And we’re +3.4% since the end of 2013.
(Just for your reference, the S&P 500 Index was +32.4% for 2013 and is +1.8% since year’s end.)
Our best performing stock was Valeant Pharmaceuticals (VRX), up 96%. VRX completed its acquisition of Bausch + Lomb, creating a global eye health platform with estimated pro-forma 2013 net revenue of more than $3.5 billion.
Thermo Fisher Scientific (TMO) and McKesson (MCK) added to our healthcare stocks’ healthy performance, returning +76% and +68% respectively. With TMO’s acquisition of Life Technologies Corp and MCK’s proposed acquisition of Celesio, the future certainly looks bright.
But remember — we still have yet to experience the Flashpoint of the Digital Revolution. We’ll only get there when the government starts encouraging innovation rather than impeding growth with new laws and regulations.
The VAP will resume a more bullish stance when stock prices, sentiment, breadth, and seasonality show signs of weakening. The market’s weakness is a contrarian’s strength.
Before you go – consider this: If you still have lots of cash in checking, savings, or money market accounts, you’re losing money to inflation. Low-yielding fixed income investments are today’s riskiest.
Sign up for my email list for more updates and to see how well the VAP performed in Q1 2014. And don’t hesitate to contact me at firstname.lastname@example.org or 732-800-2375 if you’d like any help at all.